To Assess the Glycosphingolipid Clearance and Clinical Effects of Switching to Agalsidase Beta (Fabrazyme) Versus Continuing on Agalsidase Alfa (Replagal) in Male Patients With Classic Fabry Disease

NCT04143958 · clinicaltrials.gov ↗
PHASE4
Phase
WITHDRAWN
Status
INDUSTRY
Sponsor class

Stopped The Sponsor terminated the study due to recruitment infeasibility without having enrolled any patient.

Conditions

Interventions

Sponsor

Sanofi